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Abstract: The aim of this study was to
evaluate the role of apoptosis in chronic
hepatitis B, and correlate it with disease
severity. We studied the expression of the Fas
antigen (FasAg) and Bcl-2 protein in a group
of patients with chronic hepatitis B at various
stages of the disease. Four liver biopsy
specimens taken from the patients with
chronic hepatitis B infection and five control
liver tissue specimens with normal histology
were studied. Liver specimens were scored for
disease severity according to Knodell’s hepatic
activity index (HAI). The percentage of hepatic
expression was evaluated semi-quantitively.
Our immunohistochemical study showed that
FasAg was expressed in 92.5% of liver
tissues, and detected mainly in the
hepatocytes in the periportal region, especially
at the advancing edges of areas of piecemeal
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Introduction
Apoptosis plays a significant role in the course of
hepatocyte death in acute and chronic hepatitis. Apoptosis
is involved in the removal of injured or infected
hepatocytes by the immune system as an adaptive and
beneficial process (1). In contrast to necrosis, apoptosis
is tightly controlled and regulated via several
mechanisms, including Fas/Fas ligand interaction, the
effects of cytokines, transforming growth factor beta and
the influence of the antiapoptotic protein family. FasAg is
a type I membrane protein in the tumour necrosis
factor/nerve growth factor receptor super family. The
primary function of Fas is to trigger apoptosis in various
cell types (2-4). Antiapoptotic protein Bcl-2 is located in
the mitochondrial inner envelope and prevents apoptosis
induced by various treatments. Although the functional
mechanism of Bcl-2 is still unclear, members of the Bcl-2
family exert an inhibitor effect on the Fas signalling
pathway. However, the inhibitor effect on the Fasmediated apoptotic signal remains controversial
(1,2,4,5). Hepatocytes are very sensitive to Fas-mediated

necrosis. There was a significant correlation
between hepatic expression of FasAg and the
scores of the hepatic activity index and
intensity portal inflammation (p=0.04,
p=0.02). Bcl-2 protein expression was
detected in 30% of liver tissues. Bcl-2
protein expression was found in only a few
hepatocytes in the periportal region. FasAg
and Bcl-2 protein expressions were not
detected in liver tissues with normal histology.
The present results demonstrate that Bcl-2
protein expression partially protects
hepatocytes against Fas-mediated apoptosis.
Cell cycle regulation during chronic hepatitis B
infection could be controlled by other genes,
but further studies are required.
Key Words: Fas antigen, Bcl-2 protein,
chronic hepatitis B

apoptosis. Acidophilic bodies, detected especially at the
advancing edges of areas of piecemeal necrosis, are
evidence of apoptosis. In vivo treatment with Fascontaining agents leads rapidly to fulminant hepatitis
(6,7). Severals have report demonstrated that Bcl-2 is
expressed in bile ductules and in small interlobular bile
ducts but not in normal hepatocytes (8).
In the present study, we evaluated the role of
apoptosis
in
chronic
hepatitis
B.
We
immunohistochemically studied the expression of FasAg
and Bcl-2 protein in HBV infected liver tissues.

Materials and methods
Patients
We studied 40 patients with chronic hepatitis B
infection, ranging in age from 12 to 75, and five liver
samples with normal histology were used as the control
group. The samples were selected at Department of
Pathology at Mersin University, Faculty of Medicine, and
Baflkent University, Faculty of Medicine, Turgut Noyan
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Research Hospital. All patients were seropositive for HBs
antigen, and 12 patients were seropositive for HBeAg.
Hepatitis B virus DNA polyerase activity was measured in
29 patients, and it was 812.4±142.6cpm. All patients
were seronegative for anti-HCV antibody. All control
patients were negative for HBsAg and Anti-HCV. All
samples were fixed in 10% buffered formaline,
embedded in paraffin wax and routinely processed.
Histological and immunohistochemical evaluation was
performed on all biopsy samples. Haematoxylin-eosin,
Masson’s trichrome and Gomori’s reticulum were used
for histochemical evaluation, and FasAg and Bcl-2 protein
for immunohistochemical evaluation. Two pathologists
who were unaware of the clinical findings examined the
sections independently. After the independent reviews,
each case was evaluated jointly and disagreements were
resolved by consensus. The histological activities of liver
samples were analysed according to Knodell’s Hepatic
Activity Index (HAI) scoring system (9,10).
Immunohistochemical staining procedures
Five-mm-thick sections were placed onto poly-Llysine-coated slides and air-dried overnight at room
temperature. Sections were deparaffinized in xylene and
dehydrated through graded concentrations of ethanol.
After blocking endogenous peroxidase with 0.3%
solutions of H2O2 in pH 7.5 PBS, sections were heated in
0.01 mol/l citrate buffers in a microwave pressure cooker
for 20 minutes. Then sections were incubated for 2 hours
with anti-Bcl-2 mouse monoclonal antibody (1:50
dilution, Neomarkers, Fremont, USA), and 18 hours with
anti-Fas mouse monoclonal antibody (1:10 dilution,
DAKO, Hamburg, Germany). After incubation, sections
were incubated for 30 minutes with an avidin-biotincomplex peroxidase kit for Bcl-2 protein and an LSAB kit
for FasAg (DAKO, Hamburg, Germany). The sections
counterstained with Mayer's haematoxylin. The degree of
immunopositivity was evaluated semi-quantitatively.
FasAg and Bcl-2 protein expressions in liver tissues were
graded as follows: (-) no expression, (+) lower than 10%
of all liver tissue, (++) 10% to 50% positive cells of all
liver tissue and (+++) more than 50% positive cells of all
liver tissue.
Statistical analysis
Statistical analyses were performed with the SPSS
9.00 computer package. The relation between FasAg and
Bcl-2 protein expression with the scores of HAI, lobular
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degeneration, piecemeal necrosis and portal inflammation
were analysed with the chi-square test. Differences with
p values <0.05 were considered to be statistically
significant.

Results
The mean age of the patients was 40.3±14.9 years
(range 12-75 years) with a male-to-female ratio of
1.35:1. Bcl-2 protein and FasAg expression were not
detected in liver tissues with normal histology, except in
a few hepatocytes with FasAg. Expression of FasAg and
Bcl-2 protein was detected in 92.5% (37 of the 40 liver
samples) and 30.0% (12 of the 40 liver samples) of liver
tissues respectively. FasAg was expressed mainly in the
cytoplasm and partially in the membranes of hepatocytes.
Expression was stronger in hepatocytes found in the
periportal region especially at the advancing edges of
areas of piecemeal necrosis and in those accompanied by
many infiltrating lymphocytes around them (Fig. 1).
Strong expression with FasAg was also found in groundglass hepatocytes (Fig. 2). Bcl-2 protein expression was
found in only a few hepatocytes at the periportal region
of all liver samples; however, most of the regenerated
bile ducts and the majority of lymphocytes present in the
portal area showed strong Bcl-2 protein expression (Fig.
3).
Tables 1-4 show the relation between the expression
of FasAg and Bcl-2 protein and the scores of HAI, lobular
degeneration, piecemeal necrosis and portal
inflammation. Liver specimens with higher scores of HAI,
lobular degeneration, piecemeal necrosis, and portal
inflammation showed stronger FasAg expression
(p=0.04, p=0.22, p=0.31, p=0.02 respectively).
However, only the correlation between the scores of HAI
and portal inflammation and FasAg expression was
statistically significant. No significant correlation was
found between Bcl-2 protein expression and the scores of
HAI lobular degeneration, piecemeal necrosis, and portal
inflammation (p=0.19, p=0.12, p=0.08, p=0.29
respectively).
No significant difference was found between the
expression of FasAg and Bcl-2 protein and HBV-DNA
polymerase activity (p=0.095, p=0.615). FasAg and Bcl2 protein expression did not differ between HBeAg
positive and HBeAg negative patients (p=0.122, p=0.208
respectively).
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Figure 1.

FasAg expression in hepatocytes in the
periportal region (X200 original
magnification).

Figure 2.

FasAg expression in ground-glass
hepatocytes
(X200
original
magnification).

Figure 3.

Bcl-2 expression in the cytoplasm of bile
ducts (double arrow) and lymphocytes in
the portal area. There are a few positive
stained hepatocytes (arrow) (X200
original magnification).
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Table 1.

Relation between FasAg and Bcl-2 protein expression and
the score of HAI.
Fas

Fas

(-)

(+)

(++)

(+++)

(-)

(+)

Minimal
Mild
Moderate
Severe

2
1
0
0

6
8
1
3

3
6
3
4

0
0
3
0

9
11
5
3

Total

3

18

16

3

28

(-)

(+)

(++)

(+++)

(-)

(+)

2
4
2
4

0
1
3
4

0
3
0
0

1
10
6
1

2
7
5
2

0
0
3
0

3
15
9
1

0
5
5
2

12

Total

3

18

16

3

28

12

Relation between FasAg and Bcl-2 protein expression and
the score of piecemeal necrosis.
Fas

Bcl-2

Score of
lobular deg.

Table 4.

Relation between FasAg and Bcl-2 protein expression and
the score of portal inflammation

Bcl-2

Fas

Score of
piecemeal n.

(-)

(+)

(++)

(+++)

(-)

(+)

0
1
3
4
5
6

3
0
0
0
0
0

6
5
2
1
1
3

4
5
0
1
1
5

0
0
1
0
1
1

11
8
1
2
1
5

2
2
2
0
2
4

Total

3

18

16

3

28

12

Discussion
Apoptosis plays an important role in embryonic
development, tissue remodelling, immune regulation and
tumour regression. The Bcl-2 family and death factor
family regulate apoptosis. Fas is a typical member of the
death factor family. It is reported that T lymphocytes are
important for the activation of Fas induced apoptosis in
chronic hepatitis B. Viral antigens expressed in infected
hepatocytes activate T lymphocytes, and at the end of this
process Fas-induced hepatocyte apoptosis begins. This is
a beneficial process for removing virus-infected cells, but
overexpression of FasAg may lead to fulminant hepatitis
(2, 11-14). Fas is abundantly expressed not only in the
liver but also in the heart and lungs. This system may be
also be involved in cytotoxic T lymphocyte mediated
disease in these tissues (13).
In the present study, we detected FasAg in the
hepatocytes of liver samples from the patients with
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Relation between FasAg and Bcl-2 protein expression and
the score of lobular degeneration.

Bcl-2

Score of
HAI

Table 3.

Table 2.

Bcl-2

Score of
portal infl.

(-)

(+)

(++)

(+++)

(-)

(+)

0
1
3
4

0
2
1
0

0
9
7
2

0
4
6
6

0
0
2
1

0
11
12
5

0
4
4
4

Total

3

18

16

3

28

12

chronic hepatitis B infection, but not in normal liver
tissues, except for a few positive hepatocytes. FasAg
expression was stronger in liver tissues with higher HAI
scores. Bcl-2 protein expression was found in only a few
hepatocytes in these cases, and was negative in normal
liver tissues. There are other reports with FasAg in
chronic hepatitis B and C that have similar results (1,15).
These findings suggest that Fas-mediated apoptosis plays
a significant role in liver cell death in viral hepatitis.
Expression of FasAg was stronger in hepatocytes’
cytoplasm, especially at the advancing edges of the region
in piecemeal necrosis among the lymphocytes. There was
a correlation between hepatic expression of FasAg and
intensity of portal inflammation (p=0.02). Ando et al.
demonstrated in their experimental study with HBVtransgenic mice that cytotoxic T lymphocytes bind HBsAgpositive hepatocytes and induce apoptosis in them. These
results suggest that the Fas system may be a way of
controlling apoptosis by cytotoxic T lymphocytes, and this
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continuous attack of lymphocytes may result in advancing
hepatic injury (1,16). These data support our findings of
stronger expression with FasAg in ground-glass
hepatocytes (Fig. 2)

triggering (6). Immunohistochemical studies with Bcl-2
protein expression in hepatomas have demonstrated that
Bcl-2 protein expression occurs in 6-19% of hepatomas
(17).

In cell cycle control, Bcl-2 is an important
antiapoptotic protein. But our results demonstrated that
Bcl-2 cannot prevent Fas-mediated hepatocyte apoptosis.
The great sensitivity of hepatocytes to Fas-mediated
apoptosis might be partially due to the small amount of
antiapoptotic proteins in these cells, and the expression of
Bcl-2 protein in hepatocytes during chronic inflammation
of liver allows their survival partially in a Fas-induced
apoptotic storm. Despite the broad antiapoptotic activity
of Bcl-2 in various apoptotic pathways, the ability of Bcl2 to inhibit Fas-mediated apoptotic pathways has
remained controversial. Costa et al. demonstrated that
Bcl-2 gene expression in the hepatocytes of transgenic
mice protects them against Fas-induced fulminant
hepatitis. This protective effect is the result of the
blocking of caspase-3 activity by Bcl-2 in response to Fas

In conclusion, in this study we have provided evidence
that the high prevalence of FasAg expression shown in
liver tissue with more severe necro-inflammatory activity
and Bcl-2 protein expression partially protects
hepatocytes against Fas-mediated apoptosis. It seems
beneficial, but it is possible that Bcl-2 protein provides
some transformed cells, and it may be a mechanism of
developing hepatoma from chronic hepatitis B infection
and cirrhosis.
Correspondence author:
Ayfle POLAT
Mersin University,
Faculty of Medicine,
Department of Pathology,
33070, Mersin-TURKEY
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